FDA Accepts Camurus’ Resubmitted NDA for CAM2029 in Acromegaly Endocrinology Advisor 14:36 Tue, 21 Jul
Camurus' NDA resubmission for CAM2029 in acromegaly accepted for review by the US FDA PR Newswire (Press Release) 06:26 Fri, 17 Jul
FDA advisers dismiss safety warnings, back 4 peptide treatments Dermatology Advisor 3d Pharma Health All sources
FDA says Mantralaya canteen 98% clean, Bombay High Court orders lawyers' inspection India Today 13h Mumbai India Indian Politics All sources
FDA advisory committee votes against Deramiocel for DMD Cardiomyopathy Rare Disease Advisor 8h Duchenne Capricor Therapeutics Pharma All sources
Adcomm backs Replimune melanoma drug, despite data concern pharmaphorum 16h Replimune Cancer Treatment Pharma All sources
